Key Takeaways From Nurix Therapeutics Analyst Ratings
Portfolio Pulse from Benzinga Insights
Recent analyst ratings for Nurix Therapeutics (NASDAQ:NRIX) show a mix of bullish to bearish sentiments, with an average 12-month price target of $25.00, marking a 4.17% increase from the previous target. The ratings reflect updates from analysts at Stephens & Co., RBC Capital, Baird, Needham, Morgan Stanley, HC Wainwright & Co., and Wells Fargo, indicating various actions such as maintaining, raising, and lowering ratings and price targets. Nurix Therapeutics, a biopharmaceutical company, is recognized for its innovative approach in cancer and immune disorder treatments, showing significant revenue growth and financial performance despite some challenges.
May 14, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Nurix Therapeutics has received mixed analyst ratings with an updated average 12-month price target of $25.00. The company's innovative approach in treating cancer and immune disorders, alongside a significant revenue growth, positions it positively in the eyes of analysts.
The updated analyst ratings and price targets for NRIX reflect a generally positive outlook, influenced by the company's innovative treatments and significant revenue growth. The increase in the average price target suggests analysts see potential for stock appreciation, likely impacting the stock positively in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100